The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

scientific article published in August 2001

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JAC/48.2.219
P698PubMed publication ID11481291
P5875ResearchGate publication ID11862316

P2093author name stringPhillips I
King A
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectgram-positive bacteriaQ857288
P304page(s)219-223
P577publication date2001-08-01
P1433published inJournal of Antimicrobial ChemotherapyQ6294770
P1476titleThe in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates
P478volume48

Reverse relations

cites work (P2860)
Q43183404Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid
Q36879791Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection
Q36525654Antibiotics for treatment of resistant gram-positive coccal infections
Q37000729Antimicrobial treatment for intra-abdominal infections
Q34939045Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001
Q42924831Chemical Probes of Escherichia coli Uncovered through Chemical-Chemical Interaction Profiling with Compounds of Known Biological Activity
Q36445468Children hospitalized with skin and soft tissue infections: a guide to antibacterial selection and treatment
Q38990504Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain
Q87107449Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria
Q35166213Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
Q35637066Daptomycin
Q44768109Daptomycin
Q35925535Daptomycin - a novel antibiotic against Gram-positive pathogens
Q38282725Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections
Q35771368Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
Q38898667Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus
Q40189196Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria
Q40166184Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis
Q36003721Daptomycin: a cyclic lipopeptide antimicrobial agent
Q36972980Daptomycin: a review 4 years after first approval
Q37693931Daptomycin: pharmacology and clinical use.
Q36718474Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections
Q49887078Enterococcus faecalis and pathogenic streptococci inactivate daptomycin by releasing phospholipids
Q33239640Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection
Q46908684Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves
Q40718774Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria.
Q36492244In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants
Q39792691In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis
Q42107088In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection
Q35753477New therapies for pneumococcal meningitis
Q34666658Novel agents for resistant Gram-positive infections--a review
Q35056042Novel agents for the treatment of resistant Gram-positive infections
Q36426011Oritavancin--an investigational glycopeptide antibiotic
Q45029806Physical and chemical compatibility of daptomycin with nine medications
Q48300017Preliminary study of a controllable device for subtenon drug infusion in a rabbit model.
Q36995920Telavancin: a novel lipoglycopeptide antimicrobial agent
Q33788308Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens
Q34330270The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
Q36521880Update on daptomycin: the first approved lipopeptide antibiotic

Search more.